Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

Jan Lycke12 enrolled

Overview

Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting multiple sclerosis treated with teriflunomide tablets 14 mg daily

Teriflunomide concentration in cerebrospinal fluid and serum will be determined in 12 patients with multiple sclerosis. They have been treated for at least 6 months and the sampling from blood and by spinal tap is done before dose at 8 am in 10 patients and at 12 am in 10 patients. The dependence from age, sex, and blood-brain barrier (BBB) integrity will be evaluated.The ratio between serum and cerebrospinal fluid will determine the passage over the BBB.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Multiple Sclerosis, Pharmacokinetics

Interventions

Teriflunomide 14 MGDRUG

Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with multiple sclerosis treated with teriflunomide 14 mg for at least 6 months Exclusion Criteria: * other immunosuppressive or immunomodulating drugs, other CNS diseases

Locations (1)

MS Centre

Gothenburg, Västra Götaland County, Sweden

Outcomes

Primary Outcomes

Concentration of teriflunomide in cerebrospinal fluid

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.